NEW YORK (360Dx) – San Diego-based TearLab announced yesterday that its next-generation, multiplex diagnostics platform for human tear samples has received CE marking as an in vitro diagnostic medical device.

The CE mark also covers an assay for response to dry eye disease therapy, which measures both osmolarity, a measure of solute concentration, and an inflammation biomarker.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.